AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24811940
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume ≥10 ml/kg PBW
Trial: 20670085
Drug: FDR gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDR gemcitabine (1,000 mg/m² on days 1 and 15), oxaliplatin (60 mg/m² on days 1 and 15), capecitabine (1,000 mg/m² BID on days 1-7 and 15-21)
Trial: 19440076
Drug: Nicotine administered
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine administered by cigarette smoking
Trial: 19440076
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of nicotine gum
Trial: 17342790
Drug: Lavender inhalation
RxNorm normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lavender inhalation
Trial: 17342790
Drug: Sunflower inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower inhalation
Trial: 15041620
Drug: Tramadol 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 40 mg (Group T(40))
Trial: 15041620
Drug: Tramadol 100
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg (Group T(100))
Trial: 15041620
Drug: Tramadol 200
RxNorm normalized name: TRAMADOL 200MG (RYZOLT) SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 200 mg (Group T(200))
Trial: 11352774
Drug: Lexipafant (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lexipafant (10 mg) administered intravenously over 5 min
Trial: 11352774
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously over 5 min
Trial: 8491237
Drug: Ambroxol 250
RxNorm normalized name: AMBROXOL
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol 250 mg b.d.
Trial: 8491237
Drug: Ambroxol 500
RxNorm normalized name: AMBROXOL
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol 500 mg b.d.
Trial: 31812327
Drug: Four-session intervention
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-session intervention alongside treatment-as-usual (TAU)
Trial: 31812327
Drug: Treatment-as-usual (TAU)-only
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (TAU)-only
Trial: 26013300
Drug: Hemoglobin transfusion
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin transfusion threshold of 70 g/L
Trial: 26013300
Drug: Hemoglobin transfusion
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin transfusion threshold of 90 g/L
Trial: 23374004
Drug: 153Sm isotope
RxNorm normalized name: 153SM
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 153Sm isotope monotherapy
Trial: 23374004
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (153Sm + EBRT)
Trial: 19873913
Drug: Eye acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye acupuncture combined with oral administration of compound Danshen tablets
Trial: 19873913
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of compound Danshen tablets
Trial: 16835737
Drug: Steroids/local anaesthetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids/local anaesthetics
Trial: 15213584
Drug: Methylphenidate plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate plus psychosocial treatment (parent training, counseling, social skills training, academic assistance, psychotherapy)
Trial: 15213584
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (including methylphenidate alone and with psychosocial treatment)
Trial: 30211929
Drug: Transendocardial injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TRANSENDOCARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transendocardial injection of autologous bone marrow-derived CD133+ stem cells
Trial: 25594550
Drug: Parathyroid hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parathyroid hormone (PTH) levels above the upper limit of normal (65 pg/mL)
Trial: 20838324
Drug: FAM regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAM regimen (5‐fluorouracil 600 mg/m(2) IV drip on days 1, 8, 29, and 36; doxorubicin 30 mg/m(2) IV bolus injection on days 1 and 29; mitomycin‐C 10 mg/m(2) IV bolus injection on day 1; repeated every 8 weeks)
Trial: 20838324
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX regimen (oxaliplatin 100 mg/m(2) IV drip on days 1 and 15; leucovorin 400 mg/m(2) IV drip on days 1 and 15; 5‐FU 400 mg/m(2) IV bolus injection; 5‐FU 2.4/3.0 mg/m(2) continuous IV infusion for 48 hours on day 1, 2, 15, and 16; repeated every 4 weeks for at least 4 cycles)
Trial: 20838324
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (FAM and FOLFOX regimens combined)
Trial: 10769552
Drug: 5 ppm
RxNorm normalized name: silver nitrate 55 PPM TOPICAL GEL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ppm inhaled nitric oxide
Trial: 9237711
Drug: Pn‐CRM197 vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pn‐CRM197 vaccines (5 microg)
Trial: 9237711
Drug: Pn‐CRM197 vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pn‐CRM197 vaccines (2 microg)
Trial: 9237711
Drug: Pn‐CRM197 vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pn‐CRM197 vaccines (0.5 microg)
Trial: 9237711
Drug: PS formulations
RxNorm normalized name: MENTHOL 10 mg in 100 mg / METHYL SALICYLATE 10 mg in 100 mg / EUCALYPTUS OIL 2 mg in 100 mg / CAMPHOR (NATURAL) 3 mg in 100 mg TOPICAL CREAM [Dr. Phillips Formulations Muscle Joint Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS formulations
Trial: 9237711
Drug: PS vaccines
RxNorm normalized name: Mumps vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS vaccines (5 microg)
Trial: 9237711
Drug: Pn‐CRM197 vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pn‐CRM197 vaccines
Trial: 9237711
Drug: HbOC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HbOC vaccine with Pn‐CRM197
Trial: 8218691
Drug: Calcium mupirocin
RxNorm normalized name: Mupirocin Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium mupirocin ointment (n = 170)
Trial: 8218691
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment (n = 169)
Trial: 24323641
Drug: safinamide 100
RxNorm normalized name: safinamide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: safinamide 100 mg/day
Trial: 24323641
Drug: safinamide 50
RxNorm normalized name: safinamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: safinamide 50 mg/day
Trial: 16677528
Drug: itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: itraconazole 200 mg Bid
Trial: 16677528
Drug: itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: itraconazole 200 mg qd
Trial: 12882842
Drug: Insulin 70/30
RxNorm normalized name: Insulin Human Isophane (NPH) 100 U/1 ML Subcutaneous Suspension [MIXTARD HUMAN INSULIN 70/30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin 70/30 mix plus metformin
Trial: 12882842
Drug: Triple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple oral therapy
Trial: 10827161
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of interferon‐alfa (6 MU subcutaneously 3 times weekly for 6 months followed by 3 MU for 6 months) and ribavirin (for 4, 6, or 12 months) in group C (n=129)
Trial: 10827161
Drug: Interferon‐alfa alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon‐alfa alone (12‐month course with high initial doses) in group A (n=95)
Trial: 8853768
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate 800 mg b.d. plus antibiotics (amoxycillin, metronidazole, clarithromycin, cefuroxime axetil, tetracycline, tetracycline plus metronidazole, or clarithromycin plus tetracycline) for 14 days
Trial: 30675515
Drug: Abemaciclib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib plus nonsteroidal aromatase inhibitor (AI)
Trial: 30675515
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus nonsteroidal aromatase inhibitor (AI)
Trial: 24603217
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose statin (atorvastatin 10 mg/d or equivalent, n=675)
Trial: 24603217
Drug: Intensive dose
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive dose statin (atorvastatin 20 or 40 mg/d or equivalent, n=680)
Trial: 24603217
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose statin
Trial: 24603217
Drug: Intensive dose
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive dose statin
Trial: 22066819
Drug: Dark chocolate
RxNorm normalized name: Ensure Original Dark Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark chocolate (40 g, cocoa > 85%)
Trial: 12126459
Drug: efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efavirenz 600 mg once daily without rifampicin (group A)
Trial: 12126459
Drug: efavirenz 800
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: efavirenz 800 mg once daily with rifampicin (group A-2)
Trial: 12126459
Drug: rifampicin in
RxNorm normalized name: Product containing rifampicin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rifampicin in bodyweight‐adjusted fixed‐dose combination (group B)
Trial: 10428251
Drug: Self-administered tampon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered tampon before physician-directed swabs of the cervix
Trial: 10428251
Drug: Physician-directed swab
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-directed swab testing before using the self-administered tampon
Trial: 7595108
Drug: Spinal manipulation
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulation therapy (SMT) applied by experienced physicians
Trial: 7595108
Drug: Spinal manipulation
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulation therapy (SMT) applied by novice manipulators
Trial: 2197004
Drug: 1.5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg.kg‐1 intramuscular codeine
Trial: 2197004
Drug: 4 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg.kg‐1 of ten per cent aerosol lidocaine
Trial: 7196885
Drug: Levamisole, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole, 150 mg daily for 2 consecutive days per week for 6 weeks (Group I, half received levamisole, half received placebo)
Trial: 7196885
Drug: Levamisole, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole, 150 mg daily for 2 consecutive days per week for 6 weeks (Group II, all received levamisole)
Trial: 29616621
Drug: Prototype disinfectant
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prototype disinfectant spray (0.13% w/v benzalkonium chloride and a cooling agent)
Trial: 29616621
Drug: BACTROBAN® disinfectant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BACTROBAN® disinfectant spray
Trial: 22089205
Drug: 250 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL 7.2% NaCl/6% hydroxyethyl starch (HT group)
Trial: 22089205
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL 6% hydroxyethyl starch (IT group)
Trial: 19737845
Drug: Pharmacological therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapies for control of glycemia, hyperlipidemia, and hypertension (ACCORD)
Trial: 3898976
Drug: Metronidazole 400
RxNorm normalized name: metronidazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 400 mg three times daily for 7 days
Trial: 9449871
Drug: Placebo three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times daily for 7 days
Trial: 2651509
Drug: Sustained-release terbutaline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release terbutaline, 10 mg twice daily (b.i.d.)
Trial: 2651509
Drug: Sustained-release terbutaline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release terbutaline, 10 mg b.i.d. and two puffs (400 micrograms) of budesonide, b.i.d.
Trial: 1093481
Drug: Miconazole nitrate
RxNorm normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole nitrate (2.0%) cream
Trial: 28939567
Drug: Prehospital administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prehospital administration of 180 mg ticagrelor
Trial: 28939567
Drug: In-hospital administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital administration of 180 mg ticagrelor
Trial: 17397949
Drug: Pyridostigmine (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (45 mg p.o.)
Trial: 12807346
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of D-camphor and extract from fresh crataegus berries (CCC)
Trial: 9551417
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (on-line conductivity ultrafiltrate kinetic modeling)
Trial: 9551417
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (standard treatment with fixed dialysate conductivity)
Trial: 3288866
Drug: Oral IgA-IgG
RxNorm normalized name: Igalmi Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral IgA-IgG (73% IgA and 26% IgG)
Trial: 3288866
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oral IgA-IgG)
Trial: 31209851
Drug: Topical Adapalene
RxNorm normalized name: adapalene Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel (A0.3/BPO2.5) for 48 weeks
Trial: 28438596
Drug: Dexamethasone (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.1 mg/kg)
Trial: 21819552
Drug: Knowledge of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge of BP treatment thresholds in CKD
Trial: 21819552
Drug: Knowledge of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge of BP treatment thresholds when proteinuria is factored in
Trial: 21819552
Drug: Achievement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achievement of P4P targets in patients treated with angiotensin modulating drugs
Trial: 24200407
Drug: Prolonged conservative
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged conservative treatment
Trial: 15143910
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg i.v. once daily (n=72)
Trial: 15143910
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg twice a day (n=71)
Trial: 15143910
Drug: Sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1 g every 6 hours (n=69)
Trial: 9257757
Drug: Levofloxacin (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (350 mg of levofloxacin hemihydrate)
Trial: 27918189
Drug: Mentalization-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-based therapy for parental conflict (Parenting Together)
Trial: 25250291
Drug: 5% dapsone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dapsone gel plus oral isotretinoin 20 mg daily
Trial: 25250291
Drug: Oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isotretinoin 20 mg daily (Control group with vehicle gel)
Trial: 24377217
Drug: Rehabilitation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation therapy
Trial: 16882819
Drug: Fluticasone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (2 mg via metered dose inhaler in the emergency department plus 500 microg twice daily via Diskus for 10 doses after discharge)
Trial: 16882819
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (2 mg/kg in the emergency department plus 5 daily doses of 1 mg/kg after discharge)
Trial: 31898212
Drug: Serotonin-norepinephrine reuptake
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin-norepinephrine reuptake inhibitors (SNRIs)
Trial: 9692422
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin 7500iu
Trial: 7871610
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin once daily (prophylaxis group, n = 176)
Trial: 28806194
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 3-month (PP3M) treatment
Trial: 28806194
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 1-month (PP1M) treatment
Trial: 21565464
Drug: Modafinil (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (up to 300 mg/day)
Trial: 18489665
Drug: Continuous etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuous etanercept treatment (50 mg twice weekly for 12 weeks, then 50 mg once weekly for 12 weeks)
Trial: 18489665
Drug: Interrupted etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Interrupted etanercept treatment (single round of discontinuation and re-treatment with etanercept 50 mg once weekly for the second 12 weeks)
Trial: 16717337
Drug: Double-injection axillary
RxNorm normalized name: Iva axillaris pollen
DrugBank: Iva axillaris pollen (DB10764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-injection axillary brachial plexus block
Trial: 8502513
Drug: BA +
RxNorm normalized name: Ba
DrugBank: Barium (DB12481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BA + PL (0.2 mg albuterol with placebo three times a day)
Trial: 8502513
Drug: BA +
RxNorm normalized name: Ba
DrugBank: Barium (DB12481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BA + CS (0.2 mg albuterol with budesonide three times a day)
Trial: 3318423
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of nabumetone administered at night
Trial: 3318423
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of nabumetone given at night
Trial: 3318423
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of naproxen in the morning and 500 mg at night
Trial: 3318423
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg three times daily)
Trial: 18086974
Drug: Chemoradiation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation therapy
Trial: 24912485
Drug: Standard Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Dose (SD) oseltamivir
Trial: 24912485
Drug: Double Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double Dose (DD) oseltamivir
Trial: 19289342
Drug: Medication Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Therapy Management (MTM) services for hypertension and diabetes management
Trial: 14998223
Drug: Erythropoietic agents
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietic agents
Trial: 3236744
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied dexamethasone eyedrops 0.1% with local antibiotics